Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q15796

UPID:
SMAD2_HUMAN

ALTERNATIVE NAMES:
JV18-1; Mad-related protein 2; SMAD family member 2

ALTERNATIVE UPACC:
Q15796

BACKGROUND:
The protein Mothers against decapentaplegic homolog 2, with alternative names JV18-1, Mad-related protein 2, and SMAD family member 2, is a key player in the TGF-beta signaling pathway. It regulates gene expression by binding to the TRE element in the promoter regions of TGF-beta regulated genes, potentially acting as a tumor suppressor in colorectal carcinoma.

THERAPEUTIC SIGNIFICANCE:
Given SMAD2's critical role in regulating cellular growth and its association with congenital heart defects and Loeys-Dietz syndrome 6, targeting this protein could lead to innovative treatments for these diseases. Understanding the role of SMAD2 could open doors to potential therapeutic strategies, marking a significant step forward in drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.